Syndax Pharmaceuticals (SNDX) Long-Term Investments (2017 - 2026)

Syndax Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $20.1 million for Q3 2025.

• In Q3 2025, Long-Term Investments rose 100.88% year-over-year to $20.1 million; the TTM figure through Sep 2025 stood at $20.1 million (up 100.88% YoY), while the FY2024 annual figure was $119.5 million, up 300.68% from the prior year.
• Long-Term Investments for Q3 2025 stood at $20.1 million, down from $62.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $119.5 million in Q4 2024, with the low at $5.5 million in Q4 2022.
• The 4-year median for Long-Term Investments is $20.1 million (2025), against an average of $39.9 million.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments soared 445.42% in 2023, then tumbled 36.14% in 2024.
• Syndax Pharmaceuticals' Long-Term Investments stood at $5.5 million in 2022, then jumped by 445.42% to $29.8 million in 2023, then soared by 300.68% to $119.5 million in 2024, then tumbled by 83.14% to $20.1 million in 2025.
• Business Quant data shows SNDX's Long-Term Investments at $20.1 million in Q3 2025, $62.6 million in Q2 2025, and $89.9 million in Q1 2025.